(Q44966920)

English

Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).

scientific article published on 9 August 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 December 2017

Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). (English)

1 reference

Europe PubMed Central

7 December 2017

phase III clinical trial

0 references

mantle cell lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

M Herold

1

1 reference

Europe PubMed Central

7 December 2017

A Schulze

2

1 reference

Europe PubMed Central

7 December 2017

D Niederwieser

3

1 reference

Europe PubMed Central

7 December 2017

A Franke

4

1 reference

Europe PubMed Central

7 December 2017

H J Fricke

5

1 reference

Europe PubMed Central

7 December 2017

P Richter

6

1 reference

Europe PubMed Central

7 December 2017

M Freund

7

1 reference

Europe PubMed Central

7 December 2017

B Ismer

8

1 reference

Europe PubMed Central

7 December 2017

K Dachselt

9

1 reference

Europe PubMed Central

7 December 2017

C Boewer

10

1 reference

Europe PubMed Central

7 December 2017

V Schirmer

11

1 reference

Europe PubMed Central

7 December 2017

J Weniger

12

1 reference

Europe PubMed Central

7 December 2017

R Pasold

13

1 reference

Europe PubMed Central

7 December 2017

C Winkelmann

14

1 reference

Europe PubMed Central

7 December 2017

C Klinkenstein

15

1 reference

Europe PubMed Central

7 December 2017

M Schulze

16

1 reference

Europe PubMed Central

7 December 2017

H Arzberger

17

1 reference

Europe PubMed Central

7 December 2017

K Bremer

18

1 reference

Europe PubMed Central

7 December 2017

S Hahnfeld

19

1 reference

Europe PubMed Central

7 December 2017

A Schwarzer

20

1 reference

Europe PubMed Central

7 December 2017

C Müller

21

1 reference

Europe PubMed Central

7 December 2017

Chr Müller

22

1 reference

Europe PubMed Central

7 December 2017

East German Study Group Hematology and Oncology (OSHO)

23

1 reference

Europe PubMed Central

7 December 2017

publication date

9 August 2005

1 reference

Europe PubMed Central

7 December 2017

Journal of Cancer Research and Clinical Oncology

1 reference

Europe PubMed Central

7 December 2017

132

1 reference

Europe PubMed Central

7 December 2017

105-112

1 reference

Europe PubMed Central

7 December 2017

2

1 reference

Europe PubMed Central

7 December 2017

https://scigraph.springernature.com/pub.10.1007/s00432-005-0023-2

0 references

Reporting outcomes in Hodgkin's disease and lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16088404

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16088404

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16088404

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Advanced Lymphosarcoma: Intensive Cyclical Combination Chemotherapy with Cyclophosphamide, Vincristine, and Prednisone

1 reference

https://pubmed.ncbi.nlm.nih.gov/16088404

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase acti

1 reference

https://pubmed.ncbi.nlm.nih.gov/16088404

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Non-Hodgkin lymphomas]

1 reference

https://pubmed.ncbi.nlm.nih.gov/16088404

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16088404

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current approaches to the management of non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16088404

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16088404

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/16088404

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00432-005-0023-2

1 reference

Europe PubMed Central

7 December 2017

1 reference

Europe PubMed Central

7 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44966920&oldid=1561859181"